Cargando…

CALR mutational status identifies different disease subtypes of essential thrombocythemia showing distinct expression profiles

Polycythemia vera (PV) and essential thrombocythemia (ET) are Philadelphia-negative myeloproliferative neoplasms (MPNs) characterized by erythrocytosis and thrombocytosis, respectively. Approximately 95% of PV and 50–70% of ET patients harbor the V617F mutation in the exon 14 of JAK2 gene, while abo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zini, Roberta, Guglielmelli, Paola, Pietra, Daniela, Rumi, Elisa, Rossi, Chiara, Rontauroli, Sebastiano, Genovese, Elena, Fanelli, Tiziana, Calabresi, Laura, Bianchi, Elisa, Salati, Simona, Cazzola, Mario, Tagliafico, Enrico, Vannucchi, Alessandro M., Manfredini, Rossella
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5802509/ https://www.ncbi.nlm.nih.gov/pubmed/29217833 http://dx.doi.org/10.1038/s41408-017-0010-2

Ejemplares similares

Calreticulin Ins5 and Del52 mutations impair unfolded protein and oxidative stress responses in K562 cells expressing CALR mutants
por: Salati, Simona, et al.
Publicado: (2019)

Role of miR-34a-5p in Hematopoietic Progenitor Cells Proliferation and Fate Decision: Novel Insights into the Pathogenesis of Primary Myelofibrosis
por: Bianchi, Elisa, et al.
Publicado: (2017)

Role of TGF‐β1/miR‐382‐5p/SOD2 axis in the induction of oxidative stress in CD34+ cells from primary myelofibrosis
por: Rossi, Chiara, et al.
Publicado: (2018)

miR-494-3p overexpression promotes megakaryocytopoiesis in primary myelofibrosis hematopoietic stem/progenitor cells by targeting SOCS6
por: Rontauroli, Sebastiano, et al.
Publicado: (2017)

P987: A DIFFERENT BALANCE IN OXIDATIVE STRESS RESPONSE IN CALR AND JAK2 MUTATED MYELOFIBROSIS PATIENTS CORRELATES WITH CLINICAL OUTCOME
por: Genovese, E., et al.
Publicado: (2022)

Validation of the differential prognostic impact of type 1/type 1-like versus type 2/type 2-like CALR mutations in myelofibrosis
por: Guglielmelli, P, et al.
Publicado: (2015)

Genomic Analysis of Hematopoietic Stem Cell at the Single-Cell Level: Optimization of Cell Fixation and Whole Genome Amplification (WGA) Protocol
por: Carretta, Chiara, et al.
Publicado: (2020)

Allelic imbalance in CALR somatic mutagenesis
por: Harutyunyan, A S, et al.
Publicado: (2015)

Sequential evaluation of CALR mutant burden in patients with myeloproliferative neoplasms
por: Cavalloni, Chiara, et al.
Publicado: (2017)

Deregulated expression of miR-29a-3p, miR-494-3p and miR-660-5p affects sensitivity to tyrosine kinase inhibitors in CML leukemic stem cells
por: Salati, Simona, et al.
Publicado: (2017)

P1003: PERIPHERAL BLOOD CYTOTOXIC T CELLS SHOW EARLY EXHAUSTED FEATURES IN MYELOFIBROSIS PATIENTS
por: Tavernari, L., et al.
Publicado: (2022)

Acute Lymphoblastic Leukemia Arising in CALR Mutated Essential Thrombocythemia
por: Langabeer, Stephen E., et al.
Publicado: (2016)

Splenic mass in a case of CALR‐mutated essential thrombocythemia
por: Imashuku, Shinsaku, et al.
Publicado: (2018)

Retinal neovascularization in the setting of CALR-mutation positive essential thrombocythemia
por: Heydinger, Stanton P, et al.
Publicado: (2023)

Driver mutations (JAK2V617F, MPLW515L/K or CALR), pentraxin-3 and C-reactive protein in essential thrombocythemia and polycythemia vera
por: Lussana, Federico, et al.
Publicado: (2017)

Inhibition of ERK1/2 signaling prevents bone marrow fibrosis by reducing osteopontin plasma levels in a myelofibrosis mouse model
por: Bianchi, Elisa, et al.
Publicado: (2023)

Invasive ductal breast carcinoma preceded by CALR‐positive essential thrombocythemia
por: Ali, Elrazi A., et al.
Publicado: (2021)

Coexistence of JAK2 and CALR mutations and their clinical implications in patients with essential thrombocythemia
por: Kang, Min-Gu, et al.
Publicado: (2016)

Involvement of MAF/SPP1 axis in the development of bone marrow fibrosis in PMF patients
por: Ruberti, S, et al.
Publicado: (2018)

Second primary malignancies in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 2233 patients
por: Mora, Barbara, et al.
Publicado: (2019)

The Response to Oxidative Damage Correlates with Driver Mutations and Clinical Outcome in Patients with Myelofibrosis
por: Genovese, Elena, et al.
Publicado: (2022)

Selected Parameters of Angiogenesis and the JAK2, CALR, and MPL Mutations in Patients With Essential Thrombocythemia
por: Gadomska, Grażyna, et al.
Publicado: (2018)

Essential thrombocythemia with CALR mutation and recurrent stroke: two case reports and literature review
por: Chen, Rong, et al.
Publicado: (2022)

An agenda for future research projects in polycythemia vera and essential thrombocythemia
por: Barbui, Tiziano, et al.
Publicado: (2020)

Mutated clones driving leukemic transformation are already detectable at the single-cell level in CD34-positive cells in the chronic phase of primary myelofibrosis
por: Parenti, Sandra, et al.
Publicado: (2021)

Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms
por: Pietra, D, et al.
Publicado: (2016)

Gender effect on phenotype and genotype in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis: results from the MYSEC project
por: Barraco, Daniela, et al.
Publicado: (2018)

Differences in Hematological and Clinical Features Between Essential Thrombocythemia Cases With JAK2- or CALR-Mutations
por: Kubuki, Yoko, et al.
Publicado: (2017)

Imatinib Treatment of Chronic Myeloid Leukemia Reveals a Preexisting CALR-mutated Essential Thrombocythemia
por: Blouet, Anaïse, et al.
Publicado: (2018)

Clinical course and outcome of essential thrombocythemia and prefibrotic myelofibrosis according to the revised WHO 2016 diagnostic criteria
por: Rumi, Elisa, et al.
Publicado: (2017)

MYB controls erythroid versus megakaryocyte lineage fate decision through the miR-486-3p-mediated downregulation of MAF
por: Bianchi, E, et al.
Publicado: (2015)

Mutations and thrombosis in essential thrombocythemia
por: Guglielmelli, Paola, et al.
Publicado: (2021)

JAK2 V617F, MPL, and CALR Mutations in Korean Patients with Essential Thrombocythemia and Primary Myelofibrosis
por: Kim, Bo Hyun, et al.
Publicado: (2015)

Phenotypic correlations of CALR mutation variant allele frequency in patients with myelofibrosis
por: Guglielmelli, Paola, et al.
Publicado: (2023)

Increased Plasma Levels of lncRNAs LINC01268, GAS5 and MALAT1 Correlate with Negative Prognostic Factors in Myelofibrosis
por: Fantini, Sebastian, et al.
Publicado: (2021)

Co-Culture of Hematopoietic Stem/Progenitor Cells with Human Osteblasts Favours Mono/Macrophage Differentiation at the Expense of the Erythroid Lineage
por: Salati, Simona, et al.
Publicado: (2013)

Significance of combined detection of JAK2V617F, MPL and CALR gene mutations in patients with essential thrombocythemia
por: Ji, Liying, et al.
Publicado: (2017)

Clinical and Hematological Relevance of JAK2V617F, CALR, and MPL Mutations in Vietnamese Patients with Essential Thrombocythemia
por: Vu, Hoang Anh, et al.
Publicado: (2019)

Myocardial Infarction as an Initial Presentation of Essential Thrombocythemia With Calreticulin (CALR) Mutation (None Type 1, None Type 2)
por: Afana, Mohammad, et al.
Publicado: (2023)

HRAS mutation positive multiple myeloma in the type 2 CALR mutation positive essential thrombocythemia: A case report
por: Krzysztof, Lewandowski, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_uctsalvdgblnr1mbo2ej1tmb5r